pyrazines has been researched along with Myelodysplastic Syndromes in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Furukawa, Y; Ito, R; Iwama, A; Iwano, S; Kayamori, K; Koide, S; Lennox, W; Mimura, N; Miyawaki, A; Nagai, Y; Nakajima-Takagi, Y; Oshima, M; Sakaida, E; Sheedy, J; Shinoda, D; Tohyama, K; Weetall, M; Yamaguchi, K; Yamazaki, S; Zhong, C | 1 |
| Cao, Q; Miller, J; Warlick, ED | 1 |
| Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S | 1 |
| Amrein, PC; Attar, EC; Ballen, KK; Deangelo, DJ; Fathi, AT; Foster, J; Fraser, JW; McAfee, S; Neuberg, D; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Abe, Y; Hamano, A; Hattori, Y; Miyazaki, K; Nakagawa, Y; Sekine, R; Shingaki, S; Suzuki, K; Tsukada, N | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Alimena, G; Breccia, M; Cilloni, D; D'Auria, F; Gottardi, E; Latagliata, R; Mandelli, F; Musto, P; Saglio, G; Sanpaolo, G | 1 |
| Chen, L; Li, JM; Shen, ZX; Wang, AH; Wei, L; Wu, WL; Zhao, SQ | 1 |
| Ding, T; Huang, J; Jin, J; Liu, H; Sun, X; Yang, M | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Ades, L; Berger, E; Bordessoule, D; Braun, T; Cahn, JY; Charbonnier, A; Chaury, MP; Cheze, S; Dreyfus, F; Etienne, G; Fenaux, P; Guerci-Bresler, A; Legros, L; Natarajan-Amé, S; Park, S; Ravoet, C; Schmidt, A; Stamatoullas, A; Vey, N | 1 |
| Bolanos, L; Cloos, J; Cortelezzi, A; Cuzzola, M; Fang, J; Goyama, S; Jansen, G; Mulloy, JC; Oliva, EN; Rasch, C; Rhyasen, G; Rigolino, C; Starczynowski, DT; Varney, M; Wunderlich, M | 1 |
| Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Guerciolini, R; Kantarjian, H; Koller, C; McConkey, D; Patel, G; Ruiz, SL; Thomas, D; Wright, J | 1 |
| Banti, A; Kaloutsi, V; Lazaridou, A; Terpos, E; Verrou, E; Zervas, K | 1 |
| Snively, A | 1 |
2 review(s) available for pyrazines and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
5 trial(s) available for pyrazines and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Remission Induction; Survival Rate; Thalidomide | 2013 |
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Erythroid Cells; Female; Fever; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome; WT1 Proteins | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pyrazines; Survival Analysis; Treatment Outcome | 2012 |
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Recurrence; Time Factors | 2004 |
9 other study(ies) available for pyrazines and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Decitabine; G2 Phase; Heterografts; HL-60 Cells; Humans; Mice; Myelodysplastic Syndromes; Paclitaxel; Pyrazines; Sequence Analysis, RNA; Tubulin; Tubulin Modulators; Vincristine | 2020 |
Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Treatment Outcome; Vorinostat | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Incidence; Lenalidomide; Leukemia; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Risk Factors; Thalidomide; Young Adult | 2013 |
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrations; Female; Humans; Immunosuppressive Agents; Lenalidomide; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pyrazines; Retrospective Studies; Thalidomide; Time Factors | 2014 |
Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazines; Signal Transduction; Valproic Acid | 2011 |
Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Caspases; Child, Preschool; Drug Interactions; Female; Humans; Male; Mice; Mice, SCID; Myelodysplastic Syndromes; NF-kappa B; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Signal Transduction; Tumor Cells, Cultured | 2011 |
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
Topics: Antineoplastic Agents; Autophagy; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase II as Topic; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Lysosomes; Multicenter Studies as Topic; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; TNF Receptor-Associated Factor 6 | 2012 |
Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosomes, Human, Pair 5; Female; Humans; Interleukin-4; Interleukin-6; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Platelet Count; Pyrazines; Thrombocytosis; Tumor Necrosis Factor-alpha | 2007 |
Advances in the treatment of MDS, multiple myeloma, and CLL.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Prognosis; Pyrazines; Risk Assessment; Thalidomide | 2007 |